J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cocquyt, V
Right arrow Articles by Porras, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cocquyt, V
Right arrow Articles by Porras, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Pharmacokinetics of intravenous alendronate

V Cocquyt, WF Kline, BJ Gertz, SJ Van Belle, SD Holland, M DeSmet, H Quan, KP Vyas, KE Zhang, J De Greve, and AG Porras

Alendronate is a potent bisphosphonate that has been studied for the treatment of osteoporosis and Paget's disease of the bone. To examine the pharmacokinetics of this drug, several groups of postmenopausal women were dosed intravenously in several studies. Twelve patients with metastatic bone disease were administered an intravenous dose of 10 mg of 14C-labeled alendronate (approximately 26 muCi), and plasma, feces, and urine samples were collected for 72 hours. Radioactivity was excreted almost exclusively in urine, and all of it was accounted for by alendronate. Overall recovery accounted for 47% of dose, with the remainder presumed to be retained in bone. Metabolism of alendronate was not observed. Renal clearance of alendronate was 71 mL/min. An additional 10 subjects were given repeated i.v. administrations of alendronate to demonstrate that previous exposure does not alter the pharmacokinetic behavior of the drug. Examination of the findings from these and other studies in which alendronate was administered intravenously revealed that disposition of single doses is linear in the range of 0.125 to 10 mg. With the possible exception of a somewhat greater skeletal retention of a systemically administered dose, the pharmacokinetics of i.v. alendronate were found to be similar to those of other bisphosphonates.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
A. A Licata
Discovery, Clinical Development, and Therapeutic Uses of Bisphosphonates
Ann. Pharmacother., April 1, 2005; 39(4): 668 - 677.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
J. Barrett, E. Worth, F. Bauss, and S. Epstein
Ibandronate: A Clinical Pharmacological and Pharmacokinetic Update
J. Clin. Pharmacol., September 1, 2004; 44(9): 951 - 965.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
G. A. Rodan and A. A. Reszka
Osteoporosis and Bisphosphonates
J. Bone Joint Surg. Am., August 1, 2003; 85(90003): 8 - 12.
[Full Text] [PDF]

Home page
 JNMHome page
J. A. Carrasquillo, M. Whatley, V. Dyer, W. D. Figg, and W. Dahut
Alendronate Does Not Interfere with 99mTc-Methylene Diphosphonate Bone Scanning
J. Nucl. Med., September 1, 2001; 42(9): 1359 - 1363.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Clinical Pharmacology